Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment

Samankaltaisia teoksia

• Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial
  Tekijä: Burmester, G, et al.
  Julkaistu: (2005)
• Efficacy and safety of adalimumab in the treatment of Rheumatoid Arthritis (RA) in real-life clinical practice: 1-year-results of the react study
  Tekijä: Burmester, G, et al.
  Julkaistu: (2006)
• Efficacy and tolerability of adalimumab (humira) in patients with active rheumatoid arthritis
  Tekijä: I G Salikhov, et al.
  Julkaistu: (2010-12-01)
• Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
  Tekijä: Rudwaleit, M, et al.
  Julkaistu: (2008)
• Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
  Tekijä: Rudwaleit, M, et al.
  Julkaistu: (2008)